Shanghai Xinhengrui Medical Technology Co., Ltd, a manufacturer of heart failure devices, has successfully raised close to RMB 100 million (USD 13.95 million) in a Series A financing round. The round was led by IDG Capital, with additional investments from Hygeia Capital and Everest Capital. The funds will be directed towards the clinical regulatory filing for the company’s OmniHeart percutaneous ventricular assist device, as well as research and development, clinical studies, and commercialization efforts for both existing and new product pipelines.
Advantages of OmniHeart Percutaneous Ventricular Assist Device
The OmniHeart percutaneous ventricular assist device by Shanghai Xinhengrui Medical Technology offers several distinct advantages:
- Efficient Fluid Design and High Flow Rate: The device boasts a high flow rate of above 4.0L/min, with exceptional blood compatibility. The NIH hemolysis index is reduced by 90% compared to industry standards, resulting in less blood damage and a significant performance advantage.
- Micro Implantable Motor with Independent Intellectual Property Rights: This feature offers a small size, high power density, good biocompatibility, high reliability, and the ability to operate continuously and stably for more than 7 days. This meets the treatment needs of high-risk PCI and most cardiogenic shock patients.
- Smart Safety Monitoring System: The system uses built-in algorithms to determine the position and operating status of the blood pump, enhancing the safety of the product’s continuous operation in non-operating room environments, such as ICU and transportation, and better fulfilling clinical requirements.-Fineline Info & Tech
